📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Journal Papers
Tools, techniques, organisation and culture of the CADD group at Sygnature Discovery
St-Gallay SA, Sambrook-Smith CP. J Comput Aided Mol Des. 2017 Mar;31(3):305-308. Computer-aided drug design encompasses a…
Journal Papers
Diastereoselective Synthesis of Highly Substituted, Amino- and Pyrrolidino-Tetrahydrofurans as Lead-Like Molecular Scaffolds
Dr. Steven M. Wales, Dr. Elena G. Merisor, Dr. Holly V. Adcock, Dr. Christopher A. Pearce, Dr. Ian R.
Journal Papers
Evaluation of the Biological Activity of Compounds: Techniques and Mechanism of Action Studies
Dougall, I. C,  Unitt, J. Abstract The first step in the biological assessment of compounds synthesized…
Journal Papers
Fluorescent Thermal Shift Assays for Identifying Small Molecule Ligands
Andrew D. Scott Abstract Fluorescent thermal shift assay (FTSA; also known as ThermoFluor, differential scanning…
News
Understanding & Predicting Brain Penetration for CNS-targeted Drugs
There are numerous strategies available incorporating in silico, in vitro and in vivo tools for…
Journal Papers
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D. Heightman, Valerio Berdini, Hannah Braithwaite, Ildiko M. Buck, Megan Cassidy, Juan Castro, Aurélie…
Journal Papers
Diastereoselective Synthesis of Highly Substituted, Amino‐ and Pyrrolidino‐Tetrahydrofurans as Lead‐Like Molecular Scaffolds
Authors: Dr. Steven M. Wales, Dr. Elena G. Merisor , Dr. Holly V. Adcock, Dr. Christopher…
News
Sygnature Discovery proves commitment to cyber security
Sygnature Discovery has obtained Cyber Essentials Plus certification, proving its commitment to cyber security and…
News
Sygnature Discovery Announces Expansion at Alderley Park
Sygnature Discovery is taking a significant stride forward in its ambitious expansion strategy by…
News
Sygnature Discovery annonce son expansion à Alderley Park
Sygnature Discovery franchit une étape importante dans sa stratégie d’expansion ambitieuse en établissant un…
News
Dr. Scott Pollack – Intracellular Enzyme Inhibitors in Small Drug Discovery
In conjunction with his presentation at the London Excel at ELRIG Drug Discovery…
News
Dr. Scott Pollack – IDO Inhibitors and their Pharmacological Effects
In conjunction with his presentation at the London Excel at ELRIG Drug Discovery…
News
Sygnature Discovery in multi-target drug discovery deal with Sitryx Therapeutics
Sitryx Therapeutics selects Sygnature Discovery for multi-target, integrated drug discovery collaboration. The energetic status of…
Blog
Protein Tags for Expression and Purification – What to use and pitfalls to avoid
In the quest to deliver pure recombinant protein for assay, biophysics or crystallisation, the addition…
Journal Papers
Combining two-directional synthesis and tandem reactions – Part 21: Exploitation of a dimeric macrocycle for chain terminus differentiation and synthesis of an sp3-rich library
Thomas E .Storra, Sarah J. Cully, Michael J. Rawling, William Lewis, Daniel Hamza,…
Journal Papers
Synthesis of Epibatidine Analogues by Pyrrole Diels-​Alder Reactions: Rapid Access to Azabicyclo[2.2.1]​heptane and 3,​8-​Diazabicyclo[3.2.1]​octane Scaffolds for Library Synthesis
Alexander T. Murray, Emma Packard, Andrew Nortcliffe, William Lewis, Daniel Hamza, Geraint Jones, Christopher J.
Journal Papers
Synthesis of 4-​aminotetrahydropyran scaffolds for drug discovery
Andrew Nortcliffe, Gavin D.S. Milne, Daniel Hamza, Christopher J. Moody Abstract Functionalised tetrahydropyran scaffolds were…
Journal Papers
Discovery of novel benzothienoazepine derivatives as potent inhibitors of respiratory syncytial virus
Euan A.F. Fordyce, Daniel W. Brookes, Claire-Lise Ciana, Matthew S. Coates, S. Fraser Hunt, Kazuhiro…
Journal Papers
In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection
In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection
Journal Papers
Expedient Synthesis of an Atypical Oxazolidinone Compound Library
Experience the expedient synthesis of an atypical oxazolidinone compound library. Uncover an efficient approach for generating diverse compounds, offering potential for drug development and research.
Journal Papers
Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective
Karawajczyk A., Giordanetto F., Benningshof J., Hamza D., Kalliokoski T., Pouwer K., Morgentin R., Nelson…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch